Sandisk Corporation reported an exceptional Q3 2026 with revenue rising 252% year-over-year and an adjusted gross margin of 78.4%, surpassing expectations. The growth is driven by a focus on high-value data center SSDs, strong operating leverage, and multi-year customer contracts. Management projects Q4 revenue between $7.75 billion and $8.25 billion, EPS of $30 to $33, and authorized a $6 billion share buyback while maintaining zero debt. Upcoming product launches and long-term supply deals are expected to sustain growth and reduce market cyclicality risks, supporting a strong buy rating with a $1,626 price target.
Nuvei announced it will acquire Payoneer in an all-cash deal valued at $2.75 billion, offering Payoneer shareholders $7.40 per share. The merger aims to create a global commerce platform supporting businesses in over 190 countries, enhancing payment ...
Eli Lilly announced that its Phase 3 BRUIN CLL-322 trial showed adding Jaypirca (pirtobrutinib) to venetoclax and rituximab significantly improved progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or...
The osteoarthritis market is projected to grow at a moderate CAGR of 3% from 2026 to 2036, driven by an aging population and increasing disease prevalence. Emerging therapies like LEVI-04, ZILOSUL, TissueGene-C, and others are expected to enter the m...
A class action lawsuit has been filed against Nano-X Imaging Ltd. and some of its officers, accusing them of making false and misleading statements about the company's operations and prospects between March 31, 2025, and April 17, 2026. The lawsuit c...
Rhythm Pharmaceuticals reported encouraging six-month Phase 2 trial results for setmelanotide in patients with Prader-Willi syndrome, showing improvements in BMI, body composition, hyperphagia, and behavior. The study involved 18 patients aged 6 to 2...
